Life Sciences

$2 billion deal shows growing sophistication of drug royalty sales

Latest Royalty Pharma investment shows is further evidence of the increasing IP monetisation options open to healthcare innovators

$2 billion deal shows growing sophistication of drug royalty sales
The IP dangers in life sciences collaborations and how to avoid them
14 Jun 2021

The IP dangers in life sciences collaborations and how to avoid them

Partnership agreements are a growing part of the biopharma R&D process, so anticipating potential pitfalls in such arrangements is vital

How Roche, Bristol-Myers and Pfizer use M&A to strengthen their patent positions
11 Jun 2021

How Roche, Bristol-Myers and Pfizer use M&A to strengthen their patent positions

The pharmaceutical sector has always been hot on dealmaking and the most active players continue to make serious portfolio gains in terms of volume and quality

Latest

View all
10 Jun 2021

Post-Brexit, the UK is poised to become a global biosimilars hotspot

Regulatory developments and changing attitudes at the courts make the country an increasingly attractive jurisdiction in which to launch products Read more

8 Jun 2021

South Korea’s strategic approach to IP sets up key global deals

Agreements around chips and vaccines show that IP-related issues are high on the diplomatic agendas of advanced economies Read more

1 Jun 2021

Australian patent extension pitfalls highlighted by recent decision

Ono Pharmaceutical is the latest in a series of rulings that show the need for caution when seeking all-important extension rights in the country Read more

28 May 2021

The Medicines Patent Pool – not C-TAP – is the missed opportunity for covid vaccines

A scheme premised on a rejection of the legitimacy of IP during a pandemic was never going to get the buy-in necessary to make it work Read more

News

View all
8 May 2021

Biden’s backing for the covid vaccine IP waiver should concern all rights owners

This week’s unprecedented move raises a series of worrying questions and puts in doubt the administration’s commitment to fostering innovative activity Read more

26 Apr 2021

Get smarter about covid patents or pay the price

On World IP Day it's time to get a few things straight about where the real problems in getting jabs to those who need them really lie Read more

15 Feb 2021

Uptrend in oppositions could spell costly delays for Indian patent applicants

Practitioners say greater attention to detail during the prosecution process can head off frivolous challenges Read more

18 Dec 2020

Japan’s leading corporate IP departments revealed

The country's Asia IP Elite made some big strategic shifts in 2020 as they weathered an unprecedented year Read more

Analysis

View all
27 May 2021

IBM leads on AI healthcare patent quantity while Philips is ahead on quality, data analysis shows

Life sciences companies are being left to play catch-up as tech companies build robust portfolios in anticipation of a market whose time is about to come Read more

26 May 2021

Delaware ANDA summary judgment approach not as tough as it appears

Judge Connolly is the latest in the district to announce a more restrictive approach, but a closer look reveals that there are ways through Read more

26 May 2021

Xi Jinping throws weight behind TRIPS waiver, but don’t expect China to invoke flexibilities

Chinese leader called on the WTO to make an “early decision” on whether to suspend IP protections for covid-19 vaccinations Read more

25 May 2021

Supreme Court double patenting decision worth $40 billion to Amgen

Company set to enjoy eight more years’ exclusivity on $5 billion-a-year blockbuster after the justices opt not to intervene in “gamesmanship” dispute Read more

Insights

View all
12 Aug 2020

IP market news highlights

A rundown of some of the top news stories on the IAM platform in May, June and July Read more

12 Aug 2020

As the fallout from covid continues, the two IP superpowers offer different messages

While China cheers an uptick in applications, the USPTO warns of a prolonged downturn Read more

8 Jun 2020

IP Market news highlights

IAM’s biggest spring reads Read more

8 Jun 2020

From French fancy to global community – celebrating 100 issues of IAM 

Founder and editor in chief Joff Wild looks back on 17 years of IAM Read more